Results 21 to 30 of about 8,155 (173)

Structures, targets and recent approaches in anti-leishmanial drug discovery and development. [PDF]

, 2011
Recent years have seen a significant improvement in available treatment options for leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the treatment of visceral leishmaniasis (VL) in India since 2002.
Karin Seifert, Seifert, Karin
core   +1 more source

Biological risk assessment of miltefosine in concomitant infection with opportunistic toxoplasmosis

Journal of Infection in Developing Countries, 2019
Introduction: Although miltefosine is the first line for treatment of leishmaniasis, it could have multiple un-recognized effects if any infection accidentally takes place during therapy.
Ashraf M Barakat, Amal E Saafan, Samuel T Melek, Tahany S Behour, Nehal M Khairy, Ahmed S Khairalla   +5 more
doaj   +1 more source

Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum. [PDF]

PLoS Neglected Tropical Diseases, 2017
BACKGROUND:Since miltefosine monotherapy against visceral leishmaniasis (VL) caused by Leishmania donovani has been discontinued in the Indian subcontinent due to an increase in the number of treatment failures, single dose liposomal amphotericin B is ...
Sarah Hendrickx, Magali Van den Kerkhof, Dorien Mabille, Paul Cos, Peter Delputte, Louis Maes, Guy Caljon   +6 more
doaj   +1 more source

Leishmania major Infection in Humanized Mice Induces Systemic Infection and Provokes a Nonprotective Human Immune Response [PDF]

, 2012
Background: Leishmania (L.) species are the causative agent of leishmaniasis. Due to the lack of efficient vaccine candidates, drug therapies are the only option to deal with cutaneous leishmaniasis.
Uwe Ritter (130470), Schmid, Maximilian, Hanses Frank, Ulrike Schleicher (104689), Frank Hanses, Maximilian Schmid, Florian, Christian, Frank Hanses (148604), Zimara Nicole, Wolfgang Ernst (13060), Wege, Anja Kathrin, Anja Kathrin Wege, Anja Kathrin Wege (148586), Christian Florian, Ernst, Wolfgang, Uwe Ritter, Hanses, Frank, Maximilian Schmid (148609), Florian Christian, Ritter Uwe, Nicole Zimara (148595), Zimara, Nicole, Christian Florian (148590), Schleicher, Ulrike, Ritter, Uwe, Nicole Zimara, Ernst Wolfgang, Schmid Maximilian, Schleicher Ulrike, Wege Anja Kathrin, Wolfgang Ernst, Ulrike Schleicher   +31 more
core   +2 more sources

Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol

Parasites & Vectors, 2021
Background Leishmania infantum is the most important etiological agent of visceral leishmaniasis in the Americas and Mediterranean region, and the dog is the main host.
Gustavo Gonçalves, Monique Paiva Campos, Alessandra Silva Gonçalves, Lia Carolina Soares Medeiros, Fabiano Borges Figueiredo   +4 more
doaj   +1 more source

Miltefosine: A Repurposing Drug against Mucorales Pathogens

, 2023
Mucorales are a group of non-septated filamentous fungi widely distributed in nature, frequently associated with human infections, and are intrinsically resistant to many antifungal drugs.
Luana Pereira Borba-Santos, Rodrigo Rollin-Pinheiro, Mariana Ingrid Dutra da Silva Xisto, Eliana Barreto-Bergter, Jefferson Cypriano, Yuri de Castro-Almeida, Fernanda de Ávila Abreu, Giulia Maria Pires dos Santos-Freitas, Sonia Rozental, Victor Pereira Rochetti   +9 more
core   +1 more source

Induction of Apoptosis by Miltefosine in Iranian Strain of Leishmania infantum Promastigotes [PDF]

Iranian Journal of Parasitology, 2009
Background: Miltefosine is a new drug of choice for the treatment of visceral leishmaniasis. Numerous experi­mental studies have shown miltefosine is effective on Leishmania donovani, however, effectiveness of miltefos­ine in treatment of L.
S Khademvatan, MJ Gharavi, L Akhlaghi, A Samadikuchaksaraei, K Mousavizadeh, R Hadighi, J Saki   +6 more
doaj   +1 more source

Effects of miltefosine treatment in fibroblast cell cultures and in mice experimentally infected with Neospora caninum tachyzoites [PDF]

, 2012
Miltefosine was investigated for its activity against Neospora caninum tachyzoites in vitro, and was shown to inhibit the proliferation of N. caninum tachyzoites cultured in human foreskin fibroblasts (HFF) with an IC50 of 5·2 μM.
Debache, Karim, Hemphill, Andrew
core   +2 more sources

Topical Sustained Delivery of Miltefosine Via Drug-Eluting Contact Lenses to Treat Acanthamoeba Keratitis

Pharmaceutics, 2022
This study aimed to develop a miltefosine-eluting contact lens (MLF-CL) device that would allow sustained and localized miltefosine release for the treatment of Acanthamoeba keratitis. MLF-CLs were produced in three different miltefosine doses by solvent-
Lin Chen, Liangju Kuang, Amy E. Ross, Wissam Farhat, Nikolay Boychev, Sina Sharfi, Levi N. Kanu, Longqian Liu, Daniel S. Kohane, Joseph B. Ciolino   +9 more
doaj   +1 more source

Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India. [PDF]

PLoS Neglected Tropical Diseases, 2015
BACKGROUND:Recent studies have shown significant decline in the final cure rate after miltefosine treatment in visceral leishmaniasis. This study evaluates the efficacy of miltefosine in the treatment of post kala-azar dermal leishmaniasis (PKDL ...
V Ramesh, Ruchi Singh, Kumar Avishek, Aditya Verma, Deepak Kumar Deep, Sandeep Verma, Poonam Salotra   +6 more
doaj   +1 more source